Third Quarter 2020

Corporate update and
financial results

November 10, 2020

BIONTECH

Forward-looking statements

Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects, including the Company's views with respect to the potential for mRNA and other pipeline therapeutics; BioNTech's efforts to combat COVID-19; the collaborations between BioNTech and Pfizer and Fosun to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our continuing Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data for BNT162, BNT311 and our other product candidates, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any potential approval or Emergency Use Authorization with respect to our BNT162 program; the timing for submission of BNT162 manufacturing data to the FDA; the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021 and orders received to-date; the planned next steps in BioNTech's pipeline programs and specifically including, but not limited to, statements regarding plans to initiate clinical trials of BioNTech's product candidates and expectations for data announcements with respect to BioNTech's product candidates; BioNTech's expectations with respect to interactions with regulatory authorities such as FDA and EMA, including the potential approval of BioNTech's or its collaborators' current or future drug candidates; expected royalty and milestone payments in connection with BioNTech's collaborations; BioNTech's anticipated cash usage for fiscal year 2020 and beyond; the creation of long-term value for BioNTech shareholders; and the impact of COVID-19 on clinical trials and business operations, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "expects," "plans," "potential," "target," "continue" and variations of these words or similar expressions are intended to identify forward-looking statements. Such statements are based on the current beliefs and assumptions of the management team of BioNTech and on the information currently available to the management team of BioNTech and are subject to change. The Company will not necessarily inform you of such changes. These forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause the Company's actual results, performance or achievements to be materially different than any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the Company's ability to discover and develop its novel product candidates and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates; actions of the Company's collaborators regarding continued product development and product commercialization; actions of regulatory authorities, which may affect the initiation, timing and progress of clinical trials or the ability of the Company to obtain marketing authorization for its product candidates; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of our ongoing BNT162 trial or in larger, more diverse populations upon commercialization; the Company's ability to obtain, maintain and protect its intellectual property; the Company's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; competition from others using technology similar to the Company's and others developing products for similar uses; the Company's ability to manage operating expenses; the Company's ability to obtain additional funding to support its business activities and establish and maintain its existing and future collaborations and new business initiatives; the Company's dependence on collaborators and other third parties for development, manufacture, marketing, sales and distribution of products; the outcome of litigation; and unexpected expenditures. Any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. The mRNA vaccines and other product candidates discussed in this slide presentation are investigational products being developed by BioNTech and its collaborators and are not currently approved by the FDA, EMA or any other regulatory authority.

BIONTECH

Agenda

- **Q3 Highlights**
- **BNT162 (COVID-19 vaccine program)**
- **Oncology Pipeline Update**
- **Financial Update and Outlook**

Q3 2020 Highlights

BNT 162 COVID-19 Vaccine Program

- **Achieved Success in First Interim Analysis from Phase 3 Study**
  - No serious adverse events with mild to moderate tolerability profile observed to date
- Rolling submissions ongoing to EMA, MHRA (UK) and Health Canada
- On track for Emergency Use Authorization submission to FDA as early as the third week of November
- Initiated clinical trials in Japan and China to support potential local approval
- Acquired GMP facility in Marburg, Germany intended to increase production capacity in 2021
- Commercial launch planning underway with global partners Pfizer and Fosun Pharma

Oncology Pipeline

- Promising early Phase 1 data for Next Gen Immunomodulator (BNT311) at SITC 2020
- Early Phase 1 data presented for BNT131 (SAR441000) at SITC and BNT114 at ESMO
- IND approval granted for randomized Phase 2 trial of iNeST (BNT122) in adjuvant CRC
- First patient dosed in Phase 1/2a trial of BNT411 in SCLC

Financial Update and Outlook

- Closed equity and debt financings and secured grant commitments of approximately $1.2 billion[1] (€1.0 billion) in combined gross proceeds, resulting in net cash receipts of $0.8 billion[1] (€0.6 billion) in the third quarter
- Cash position of $1.2 billion[1] (€1.0 billion) on the balance sheet at end of Q3 2020

[1] Amounts translated using the exchange rate published by the German Central Bank (*Deutsche Bundesbank*) in effect as of the date of transaction, if closed; otherwise as of September 30, 2020

Agenda

- **Q3 Highlights**
- **BNT162 (COVID-19 vaccine program)**
- **Oncology Pipeline Update**
- **Financial Update and Outlook**

COVID-19 vaccine development timeline

Primary Efficacy Endpoint:

To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 in participants with (and without) evidence of infection before vaccination

SARS-CoV-2 Genetic Sequence

Made Public
January 12, 2020

COVID-19 mRNA Vaccine Program Initiation

January 27, 2020

Collaborations

Fosun Pharma:
March 16, 2020

Pfizer:
March 17, 2020

Phase 1 / 2a Trial

Germany Started April 23, 2020
- Up to 200 subjects aged 18 – 55

U.S. Started May 4, 2020
- Up to 360 subjects aged 18 – 85

Candidate/ Dose Selection

BNT162b2
July 24, 2020

FDA Fast Track designation

July 13, 2020

Initiated Pivotal Phase 2b / 3 Trial

July 27, 2020 Start with up to 44,000 subjects

Initiated Rolling Submissions

EMA: October 6, 2020
Canada: October 7, 2020
UK: October 9, 2020

Interim analysis finds evidence of efficacy

November 9, 2020

Interim analysis finds more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection

BIONTECH

BNT162b2 Phase 3 trial



Primary Efficacy Objectives
Efficacy against confirmed COVID-19 in participants without evidence of infection before vaccination
Efficacy against confirmed COVID-19 in participants with and without evidence of infection before vaccination

- **Interim analysis of unblinded data by independent data monitoring committee on Nov 8, 2020 :**
  - 94 disease cases accrued, split of disease cases indicates >90% Vaccine Efficacy
  - Benign safety profile
- **Final efficacy analysis at 164 disease cases expected end of November, 2020**
- **Vaccinated participants will continue to be monitored for up to 2 years**

43,538 participants enrolled
38,955 received 2nd dose

Race/Ethnicity	Overall Study
Asian	5%
Black	10%
Hispanic/Latinx	26%
Native American	0.8%

Data as of November 08th, 2020

BNT162: Global development program expanded to additional regions



Regulatory submission on a rolling basis to EMA, MHRA (UK) and Health Canada initiated in October

[1]Phase 1/2 remains ongoing in U.S. and EU

BNT162: Global commercial supply commitments*

- **> 570 million doses** committed* for 2020 and 2021 in 13 countries and the EU with an option to purchase an **additional 600 million doses**
- Additional **commercial discussions ongoing** with multiple **countries** and supranational organizations including **COVAX**

Commercial supply commitments*		
Region	**Number of Doses**	**Order value**
Canada	Not disclosed	Not disclosed
EU	200 million with option for additional 100 million	Not disclosed
Japan	120 million	Not disclosed
United Kingdom	30 million	Not disclosed
United States	100 million with option for additional 500 million	$1.95 billion for first 100 million doses
Nine additional countries	Not disclosed	Not disclosed

* Subject to clinical success and regulatory approval

BNT162: Distribution model

Packaging

Thermal shipping and GPS-tracking

Thermal shipper (packaging designed to maintain crucial conditions) keeps product at ultra-low temperature for up to 10 days if stored at +15°C to +25°C without opening and up to 15 days if opened and then re-iced

Distribution

Specialized supply chain providers for air and ground shipping



Storage at Point of Care

Thermal Shipper
BNT162b2 can be stored for up to 15 days on re-icing

Ultralow Temperature Freezer
Commercially available
Store BNT162b2 as frozen liquid at -70oC (+/- 10oC) for up to 6 months

Refrigerator (+2-8°C)
BNT162b2 can be stored for up to 5 days after transfer from shipper or freezer

Stability testing of BNT162b2 ongoing

BIONTECH

Agenda

- **Q3 Highlights**
- **BNT162 (COVID-19 vaccine program)**
- **Oncology Pipeline Update**
- **Financial Update and Outlook**

Oncology pipeline: Expanded to 11 product candidates in 12 clinical trials

Drug class	Platform	Product Candidate	Indication (Targets)	Pre-clinical / Phase 1 / Phase 2	Rights / Collaborator
mRNA	FixVac (fixed combination of shared cancer antigens)	**BNT111**	advanced melanoma		fully-owned (Regeneron)
		BNT112	prostate cancer		fully-owned
		BNT113	HPV16+ head and neck cancer[1]		fully-owned
		BNT114	triple negative breast cancer		fully-owned
		BNT115	ovarian cancer[1]		fully-owned
	iNeST (patient specific cancer antigen therapy)	**RO7198457 (BNT122)**	1L melanoma		Genentech (global 50:50 profit/loss)
			multiple solid tumors		
	Intratumoral Immunotherapy	**SAR441000 (BNT131)**	solid tumors *(IL-12sc, IL-15sushi, GM-CSF, IFNα)*		Sanofi (global profit/loss share)
Antibodies	**Next-Gen CP[2] Immunomodulators**	**GEN1046 (BNT311)**	multiple solid tumors *(PD-L1×4-1BB)*		Genmab (global 50:50 profit/loss)
		GEN1042 (BNT312)	multiple solid tumors *(CD40×4-1BB)*		
	Targeted Cancer Antibodies	**BNT321 (MVT-5873)**	pancreatic cancer (sLea)		fully-owned
SMIM[3]	**Toll-Like Receptor Binding**	**BNT411**	solid tumors *(TLR7)*		fully-owned

- BNT111: Clinical data published in *Nature* (July 2020); subsequent announcement of Regeneron collaboration
- BNT114 data update for TNBC-MERIT trial at ESMO Virtual Congress 2020
- BNT131 data update from Phase 1 presented at SITC
- **BNT311 Interim update from Phase 1 presented at SITC**
- BNT411 FPD in Phase 1/2 trial in ES-SCLC

[1]BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials.
[2]Checkpoint Inhibitor.
[3]Small Molecule Immunomodulators.

BIONTECH

We plan to initiate multiple FIH[1] trials for our preclinical product candidates in 2021

Drug class	Platform	Product Candidate	Indication (Targets)	Rights Collaborator	Milestones
Oncology					
mRNA	**FixVac**	BNT116	NSCLC	fully-owned	
	RiboMabs (mRNA-encoded antibodies)	BNT141	multiple solid tumors	fully-owned	**Phase 1 start in 1H 2021**
		BNT142	multiple solid tumors *(CD3+CLDN6)*	fully-owned	Phase 1 start in 2H 2021
	RiboCytokines (mRNA-encoded Cytokines)	BNT151	multiple solid tumors *(optimized IL-2)*	fully-owned	**Phase 1 start in 1H 2021**
		BNT152, BNT153	multiple solid tumors *(IL-7, IL-2)*	fully-owned	**Phase 1 start in 1H 2021**
Cell Therapies	**CAR-T Cells**	BNT211	multiple solid tumors (*CLDN6)*	fully-owned	**Phase 1/2a start in 2H 2020**
		BNT212	pancreatic, other cancers *(CLDN18.2)*	fully-owned	
	Neoantigen-based T cell therapy	BNT221 (NEO-PTC-01)	multiple solid tumors	fully-owned	**Phase 1 start in 1H 2021**
	TCRs	to be selected	all tumors	fully-owned	
mRNA	**Infectious Disease Immunotherapies**	BNT161	influenza	Pfizer	
		undisclosed	up to 10 indications	Penn[3]	
		undisclosed	HIV and tuberculosis	Bill & Melinda Gates Foundation	
	Rare Disease PRT[2]	BNT171	not disclosed	Genevant (global 50:50 profit/loss)	
		undisclosed	4 additional rare disease indications		

We expect to initiate multiple Phase 1 trials in 2021

[1] FIH = First in Human; [2] PRT = Protein Replacement Therapy; [3] We are eligible to receive worldwide licenses

BIONTECH

BNT311: Next-generation bispecific antibody PD-L1x4-1BB



- First-in-class, next generation **checkpoint immunotherapy** designed to **enhance T cell** and **NK cell function** through **conditional 4-1BB co-stimulation** while **simultaneously** blocking **T cell axis**
- Enhances **proliferation** and **cytokine production** of **activated T cells**, activates immune cells in **tumor-draining lymph nodes,** and induces **tumor regression** *in vivo*

BNT311: Safety Trial in Patients With Malignant Solid Tumors (NCT03917381)

Phase 1
Dose Escalation
N = 61

Metastatic or unresectable solid tumors in patients who are not candidates for standard therapy

Cycle
Q3W



BNT311/GEN1046: intravenous flat dose every 3 weeks until disease progression or unacceptable toxicity

Study Endpoints

Safety and tolerability
PK/PD
Anti-tumor activity
Biomarkers

Phase 2a
Dose Expansion
N = Up to 40 per cohort

EC1: NSCLC ≤ 2-4L p. ICI
EC2: NSCLC ≤ 2-4L ICI n.
EC3: Urothelial Ca ≤ 2-4L p. ICI
EC4: Endometrial Ca ≤ 2-4L ICI n.
EC5: TNBC ≤ 2-4L CPI n./ p. ICI
EC6: SCCHN ≤ 2-4L CPI n./ p. ICI
EC7: Cervical Ca ≤ 2-4L ICI n.

p. ICI = post immune checkpoint inhibition
CPI n. = check point inhibitor naive

BIONTECH

BNT311: Phase 1 / 2a - Dose Escalation Patient Demographics

Dose Escalation Cohort	All patients N=61
Median age, years (range)	**59 (23, 79)**
Age group, n (%)	
<65 years	**44 (72.1)**
≥65 years	**17 (27.9)**
Female, n (%)	**28 (45.9)**
Cancer type, [a] n (%)	
Colorectal cancer	**12 (19.7)**
Ovarian cancer	**9 (14.8)**
Pancreatic cancer	**6 (9.8)**
NSCLC	**6 (9.8)**
Other	**28 (45.9)**
Median number of prior regimens, (range)	**3 (1–11)**
Prior treatment with PD-(L)1 inhibitor, n (%)	**23 (37.7)**

- A total of 61 patients were enrolled in the dose escalation part of the trial
- Patients were heavily pretreated, receiving a median (range) of 3 (1–11) treatments; nearly 40% had received prior PD-(L)1 treatment

BIONTECH

BNT311: Phase 1 / 2a - Safety profile

TEAEs occurring in ≥10% of patients



TRAEs occurring in ≥10% of patients

Dose escalation cohort	All patients (N=61)		
	All grades, n (%)	Grade 3, n (%)	Grade 4, n (%)
Any TRAE	43 (70.5)	15 (24.6)	3 (4.9)
TRAEs in ≥10% of patients, by preferred term			
Transaminase elevation	16 (26.2)	6 (9.8)	0
Hypothyroidism	11 (18.0)	0	1 (1.6)
Fatigue	8 (13.1)	1 (1.6)	0

- The most common treatment-related adverse events were transaminase elevations, hypothyroidism and fatigue
- Treatment-related transaminase elevations occurred in 26.2% of patients (9.8% of patients had grade 3 transaminase elevations)
- There were no patients with Grade 4 transaminase, or treatment-related bilirubin increases
- MTD has not been reached

BNT311: Phase 1 / 2a - Pharmacodynamics

Modulation of peripheral pharmacodynamic markers



- Pharmacological activity was observed across a broad range of dose levels
- Increased levels of peripheral IFN-g and IP-10, increased frequency of proliferating (Ki67+) total CD8 and effector memory CD8+ T cells were observed

Data extraction: June 26, 2020.
Maximal fold-change from baseline measured during cycle 1. Lower doses correspond to dose levels ≤200 mg and higher doses correspond to dose levels ≥400 mg.
Wilcoxon-Mann-Whitney test.
IFN, interferon; IP-10, interferon-gamma–inducible protein 10.

BIONTECH

BNT311: Phase 1 / 2a - Anti-tumor Activity: Dose escalation

Best percent change from baseline in tumor size



Disease control achieved in 65.6% of patients; four patients with PR

Includes 4 early partial responses in TNBC (1), ovarian cancer (1), and ICI-pre treated NSCLC (2) patients

Data cut-off: September 29, 2020. Post-baseline scans were not conducted for five patients.
[a]Minimum duration of response (5 weeks) per RECIST v1.1 not reached.
[b]PR was not confirmed on a subsequent scan.
NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; SD, stable disease; SoD, sum of diameters; uPR, unconfirmed partial response.

BIONTECH

19

BNT311: Phase 1 / 2a - Anti-tumor activity in immune checkpoint recurrent/refractory NSCLC Expansion



As of October 12, 2020, 24 patients were enrolled in expansion cohort 1, which includes patients with NSCLC with progression on or after ICI therapy

- 12 patients had post-baseline scans; 6 patients were still on treatment with BNT311/GEN1046, 6 patients discontinued
- Preliminary efficacy in 12 patients who could be objectively assessed showed two patients who achieved confirmed PR, one with unconfirmed PR, and four patients with SD

Data cut-off: October 12, 2020.
*Denotes patients with ongoing treatment.
aPR was not confirmed by a subsequent scan.
Includes all patients who had at least one post-baseline tumor assessment (schedule is every 6 weeks), and thus could be assessed for clinical benefit; 6 of 12 patients are still on treatment.
BOR, best overall response; ICI, immune checkpoint inhibitor; NA, not available, NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SoD, sum of diameters; TPS, tumor proportion score; uPR, unconfirmed partial response.

Agenda

- **Q3 Highlights**
- **BNT162 (COVID-19 vaccine program)**
- **Oncology Pipeline Update**
- **Financial Update and Outlook**

Third Quarter 2020 Financial Results (unaudited) – Profit and Loss

(in millions) [1]	Three months ended September 30,		Nine months ended September 30,	
	2020	2019	2020	2019
Revenues resulting from collaboration and license agreements	€ 59.6	€ 22.2	€ 113.4	€ 64.3
Revenues from other sales transactions	7.9	6.4	23.5	16.3
Total revenues	**€ 67.5**	**€ 28.7**	**€ 136.9**	**€ 80.6**
Cost of sales	(6.9)	(4.3)	(18.4)	(12.9)
Gross profit	**€ 60.6**	**€ 24.4**	**€ 118.5**	**€ 67.7**
Research and development expenses	(227.7)	(50.4)	(388.0)	(161.0)
Sales and marketing expenses	(4.3)	(0.7)	(7.7)	(1.9)
General and administrative expenses	(23.3)	(10.6)	(58.0)	(34.5)
Other operating income less expenses	8.3	0.4	8.6	1.2
Finance income less expenses	(21.1)	6.8	(24.8)	7.6
Income taxes	(2.5)	0.0	(0.3)	0.0
Loss for the period	**€ (210.0)**	**€ (30.1)**	**€ (351.7)**	**€ (120.9)**

[1] Numbers have been rounded; numbers presented may not add up precisely to the totals

BIONTECH

Third Quarter 2020 Financial Results (unaudited) – Balance Sheet

Balance Sheet Position

- Cash and cash equivalents of €990.5 million ($1,159.7 million[1]) as of September 30, 2020
- On July 27, 2020, BioNTech closed an underwritten offering of 5,500,000 American Depositary Shares ("ADSs"), each representing one of BioNTech's ordinary shares, at a public offering price of $93.00 per ADS, for gross proceeds of €435.0 million ($511.5 million[1])
- On August 28, 2020, BioNTech and a fund associated with Temasek closed a €100.0 million ($119.2 million[1]) investment in a 4-year mandatory convertible note. Temasek and another accredited investor contributed a private investment of €123.9 million ($146.0 million[1]) in ordinary shares
- On September 15, 2020 BioNTech secured grant funding of up to €375.0 million ($439.1 million[1]) in milestone-based funding from the BMBF[2] to support and accelerate the BNT162 vaccine program execution. As funding for the grant occurs subsequent to quarter end and is subject to draw downs, this funding is not reflected in the cash and cash equivalent balance as of September 30, 2020

2020 Full Year Financial Guidance

- BioNTech expects net cash used in operating activities and for purchases of property, plant and equipment to be within the previously guided range of €450 million and €600 million for the full year 2020 – likely to hit upper end of range due to acquisition of manufacturing facility

[1] Amounts translated using the exchange rate published by the German Central Bank (*Deutsche Bundesbank*) in effect as of the date of transaction, if closed; otherwise as of September 30, 2020
[2] German Federal Ministry of Education (*Bundesminsterium für Bildung und Forschung)*

Positioned for transformative 2021

- Focused on executing ongoing BNT162 **Phase 3 trial and regulatory submission processes globally**
- **Commercial preparation activities** for manufacturing and global distribution progressing for BNT162 with partners Pfizer and Fosun

- Advancing **oncology** pipeline towards **multiple late-stage clinical trial initiations**
- **Additional first-in-human trials** of novel product candidates expected **across proprietary platforms**

- **Well capitalized** to deliver on key **commercial, operational and pipeline milestones**
- **Transformational opportunity** ahead to positively impact the world – and **accelerate our long-term vision** to build a next generation immunotherapy leader

BIONTECH

Q&A

BIONTECH